Skip to Main Content

Paper Details

MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma.
Neurooncol Adv
4
2021
Cho, Choline, GBM, Lac, Lactate, N-acetylaspartate, NAA, bevacizumab, glioblastoma, patient, patients, rGBM, recurrent, tumor
Author NameAffiliation
Mark VangelAthinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital
Mark VangelHarvard Medical School
Otto RapalinoAthinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital
Otto RapalinoHarvard Medical School
Isabel Arrillaga-RomanyHarvard Medical School
Isabel Arrillaga-RomanyMassachusetts General Hospital, Cancer Center
Jayashree Kalpathy-CramerAthinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital
Jayashree Kalpathy-CramerHarvard Medical School
Bruce R RosenAthinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital
Bruce R RosenHarvard Medical School
Bruce R RosenAthinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital
Bruce R RosenHarvard Medical School
Tracy T BatchelorHarvard Medical School
Tracy T BatchelorMassachusetts General Hospital, Cancer Center
Tracy T BatchelorHarvard Medical School
Tracy T BatchelorMassachusetts General Hospital, Cancer Center
  • 1 - 16

Datasets

Release 1.2